Fewer Analysts, Forgotten Small-Caps
Executive Summary
A selection of Europe's biotech analysts describe to In Vivo Europe Rx how the market downturn and shrinking analyst community is affecting their coverage of the sector--and leaving small stocks ignored.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?